Navigation Links
SuperGen to Present Data at EORTC-NCI-AACR
Date:10/15/2008

DUBLIN, Calif., Oct. 15 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the company's plans to present five posters at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" on October 23 and 24, 2008.

SuperGen's presentations will review clinical and non-clinical advances in the following compounds: MP-470, SGI-1776 and SGI-1252. All presentations will occur as poster presentations.

Abstract Number/Title Date

Abstract 403: Clinical responses in highly refractory

solid tumor patients with oral MP-470, a multi-targeted

tyrosine kinase inhibitor, in combination with standard

of care chemotherapy regimens: preliminary report from

a multi-institutional phase-1b clinical trial Oct 23

Abstract 332: In vivo activity of SGI-1776, an orally

active Pim kinase inhibitor Oct 23

Abstract 426: Effects of food on the single-dose

pharmacokinetics of oral MP-470 capsules Oct 23

Abstract 480: MP-470, a novel multi-targeted tyrosine

kinase inhibitor targeting RAD 51 is not toxic to human

primary marrow stem cells at clinically relevant

concentrations Oct 24

Abstract 571: Modulation of JAK2 signaling pathways in

vitro and in vivo by SGI-1252, a potent small molecule

JAK2 inhibitor Oct 24

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts:

SuperGen, Inc. Dorland Global Public Relations

Timothy L. Enns Michael Beckerich (Media)

SVP, Corporate Communications Tel: (212) 677-7632

& Business Development mbeckerich@dorland.com

Tel: (925) 560-0100

Email: tenns@supergen.com

Mary M. Vegh

Manager, Investor Relations

Tel: (925) 560-2845

E-mail: mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
2. SuperGen Reports 2008 Second Quarter Financial Results
3. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
4. SuperGen Reports 2008 First Quarter Financial Results
5. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
6. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
7. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
8. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
9. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
10. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
11. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... ... compliance training, today announced an interactive FDA compliance training course, ... (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on ...
(Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced today that Edward Lanphier , Sangamo,s president ... the progress of Sangamo,s ZFP Therapeutic ® development ... at 2:40 pm ET on Thursday, February 11, 2016, ... Healthcare Conference. The conference is being held in ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... takes place February 5-6 at the University’s student center, Kehr Union, located ... as workshops and competitions for ample networking, learning and collaborating opportunities. , ...
(Date:2/4/2016)... 4, 2016  CytoSorbents Corporation (NASDAQ: CTSO ... flagship CytoSorb® blood filter to treat deadly inflammation ... world, announced that CEO Dr. Phillip Chan ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... Conference Presentation Details: Where: Convene ...
Breaking Biology Technology:
(Date:1/27/2016)... WEST CHESTER, Ohio , Jan. 27, 2016 /PRNewswire/ ... services supplier based in West Chester, Ohio ... and their award winning service staff, based in ... Track,s technical capacity and ability to provide modifications, installations ... John Dovalina , CEO of PLUS, commented, "PLUS ...
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
Breaking Biology News(10 mins):